Thyrotropin receptor antibody (TRAb) (TRAb)

Circulating anti-TSHR autoantibodies are pathogenic immunoglobulins that target the thyrotropin receptor (TSHR), primarily on thyroid follicular cells. In Graves' disease, these antibodies act as functional analogs of thyroid-stimulating hormone (TSH), constitutively activating the receptor and causing hyperthyroidism (Smith & Hegedüs, 2016, NEJM). They are also implicated in the pathogenesis of Graves' orbitopathy by stimulating TSHR in orbital fibroblasts, leading to hyaluronan production and inflammation (Bahn, 2010, NEJM). Clinical management involves measuring these antibodies to diagnose autoimmune thyroid disease and assess the risk of relapse or neonatal thyrotoxicosis (Kahaly et al., 2018, European Thyroid Journal). Emerging therapies like K1-70 directly block these antibodies, while others like Imlifidase enzymatically degrade them to rapidly reduce their pathogenic effects (Latif et al., 2020, Frontiers in Endocrinology). Additionally, B-cell depleting agents like Rituximab are used to lower the production of these autoantibodies in refractory cases (Salvi et al., 2015, European Journal of Endocrinology). The presence of these antibodies is a hallmark of thyroid autoimmunity and serves as a critical biomarker for therapeutic efficacy.

Other names

Thyroid-stimulating immunoglobulin (TSI)Thyrotropin-binding inhibitory immunoglobulin (TBII)Thyroid-blocking immunoglobulin (TBI)TSH receptor antibodyAnti-TSHR autoantibody

Competitive inhibition of autoantibody binding to the thyrotropin receptor; enzymatic cleavage of circulating IgG; depletion of B-lymphocytes to reduce autoantibody synthesis.